Scopul nostru este sprijinirea şi promovarea cercetării ştiinţifice şi facilitarea comunicării între cercetătorii români din întreaga lume.
Autori: Purice M, Ursu IH, Baicus C, Goldstein A, Niculescu DA
Editorial: Acta Endocrinologica, Vol VI, No4, 431-442, 2010, 2010.
The aim of the study was to evaluate prevalence of hyerhomocysteinemia in hypothyroid patients and the effect of folic acid supplementation when serum homocysteine was over risk level .
Subjects with moderate(Group1) and severe hypothyroidism(Group2) were evaluated before any therapy and after 6 months of combined folic acid with levothyroxine substitution. Homocysteine (Hcy), folic acid, thyroid hormones, lipids were measured for all subjects. Thyroglobulin, antithyroglobulin were measured only for Group2.
Only 17 % of the subjects had basal homocysteine at non risk level (< 10 μmol/L). Higher Hcy levels than for control (p <0.0001) were found. In group 1 basal level of serum folic acid was lower than in control group and group2 (p<0.001). No correlation was found between high levels of Hcy (> 12 μmol/L ) and positive thyroglobulin. After 3 month of combined therapy, significant decrease of Hcy (p<0.0001) was observed compared with the basal level. Normalization of Hcy appears during next 3 month even with reducing the Folic acid supplementation. In conclusion our results reports moderate hyperhomocysteinemia in hypothyroid patients. This may exacerbate the cardiovascular risk traditionally attributed to lipid changes. Six month of combined therapy (L-thyroxine and folic acid) corrected hyperhomocysteinemia excluding the additional risk.
Cuvinte cheie: of hyerhomocysteinemia in hypothyroid patients